Thus, our data unveil the upregulation of the selected AATs (SLC1A5/ASCT2, SLC7A5/LAT1, and SLC38A2/SNAT2) as a prognostic marker of poor survival of patients with CRC, useful for cancer patient stratification, in particular with regard to the KRAS mutant subtype of patients. This evidence concerns the gene SLC1A5 and cancer.